A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major

Clinical trial NCT06291961 · COMPLETED

Trial details

NCT number: NCT06291961
Sponsor: CorrectSequence Therapeutics Co., Ltd
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Beta-Thalassemia Major

Start date: 2024-04-18
Primary completion: 2025-11-17
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.